Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales

Reuters

11/05

Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales

Overview

Geron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO sales
Net loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024
Operating income for Q3 2025 beats analyst expectations

Outlook

Company expects 2025 operating expenses between $250 mln and $260 mln
Company anticipates IMpactMF interim analysis in H2 2026
Geron believes existing resources and RYTELO sales will fund future operations

Result Drivers

RYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demand

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Product Revenue		$47.16 mln
Q3 EPS		-$0.03
Q3 Net Income		-$18.42 mln
Q3 Operating Income	Beat	-$13.88 mln	-$17.30 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15

Press Release: ID:nBw2h2mvSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2581721266"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581721266\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581721266?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581721266","market":"fut","top_or_hot":-1,"title":"Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales </title></head><body><p><span>Overview</span></p><ul><li><p>Geron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO sales</p></li><li><p>Net loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024</p></li><li><p>Operating income for Q3 2025 beats analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects 2025 operating expenses between $250 mln and $260 mln</p></li><li><p>Company anticipates IMpactMF interim analysis in H2 2026</p></li><li><p>Geron believes existing resources and RYTELO sales will fund future operations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demand</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$47.16 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.03</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.42 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$13.88 mln</p></td><td><p>-$17.30 mln (7 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15</p></li></ul><p>Press Release: <span>ID:nBw2h2mvSa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-11-05 20:08</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales </title></head><body><p><span>Overview</span></p><ul><li><p>Geron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO sales</p></li><li><p>Net loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024</p></li><li><p>Operating income for Q3 2025 beats analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects 2025 operating expenses between $250 mln and $260 mln</p></li><li><p>Company anticipates IMpactMF interim analysis in H2 2026</p></li><li><p>Geron believes existing resources and RYTELO sales will fund future operations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demand</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$47.16 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.03</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.42 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$13.88 mln</p></td><td><p>-$17.30 mln (7 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15</p></li></ul><p>Press Release: <span>ID:nBw2h2mvSa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GERN","symbol_name":"傑龍","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0KN:1","article_id":"2581721266","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581721266","pubTimestamp":1762344501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO salesOverviewGeron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO salesNet loss for Q3 2025 narrows to $18.4 mln fro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GERN":"杰龙","BK4139":"生物科技"},"translate_title":"血液学药物开发商Geron Q3净亏损收窄，受RYTELO销售推动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GERN":0.9},"content_text":"Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales OverviewGeron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO salesNet loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024Operating income for Q3 2025 beats analyst expectationsOutlookCompany expects 2025 operating expenses between $250 mln and $260 mlnCompany anticipates IMpactMF interim analysis in H2 2026Geron believes existing resources and RYTELO sales will fund future operationsResult DriversRYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demandKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Product Revenue$47.16 mlnQ3 EPS-$0.03Q3 Net Income-$18.42 mlnQ3 Operating IncomeBeat-$13.88 mln-$17.30 mln (7 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15Press Release: ID:nBw2h2mvSaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}